^
BIOMARKER:

FGFR3 mutation

i
Other names: FGFR3, ACH, CD333, CEK2, JTK4, Fibroblast growth factor receptor 3
Entrez ID:
FGFR3 mutation
Urothelial Cancer
erdafitinib
Sensitive: A1 - Approval
FGFR3 mutation
Urothelial Cancer
BAY1163877
Sensitive: B - Late Trials
FGFR3 mutation
Cholangiocarcinoma
erdafitinib
Sensitive: C1 - Off-label
FGFR3 mutation
Gastric Cancer
erdafitinib
Sensitive: C1 - Off-label
FGFR3 mutation
Urothelial Cancer
infigratinib
Sensitive: C2 – Inclusion Criteria
FGFR3 mutation
Urothelial Cancer
pemigatinib
Sensitive: C2 – Inclusion Criteria
FGFR3 mutation
Bladder Cancer
infigratinib
Sensitive: C2 – Inclusion Criteria
FGFR3 mutation
Breast Cancer
infigratinib
Sensitive: C2 – Inclusion Criteria
FGFR3 mutation
Urothelial Cancer
TAS 120
Sensitive: C2 – Inclusion Criteria
FGFR3 mutation
NSCLC
Immunotherapy
Sensitive: C3 – Early Trials
FGFR3 mutation
NSCLC
nintedanib
Sensitive: C3 – Early Trials
FGFR3 mutation
Urothelial Cancer
B-701
Sensitive: C3 – Early Trials
FGFR3 mutation
Urothelial Cancer
enfortumab vedotin
Resistant: C3 – Early Trials
FGFR3 mutation
Solid Tumor
CPL304110
Sensitive: D – Preclinical
FGFR3 mutation
Endometrial Cancer
infigratinib
Sensitive: D – Preclinical
FGFR3 mutation
Urothelial Cancer
dasatinib + infigratinib
Sensitive: D – Preclinical